+1-888-308-5802     
News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Soldo Financial Services bags US $61million in Series B Funding

Published Date: 2019-07-10         Author: Pankaj Singh

Soldo will use the recent investment to expand across the U.K., Ireland and Italy, It also plans to enter new European markets and double its workforce over the next 12 months. Soldo Financial Services Ltd., a British fintech startup working to streamline businesses expense management... Read More

Dubai-based truck aggregator Trukkin raises over $3.5 million

Published Date: 2019-05-27         Author: Pankaj Singh

Trukkin, a Dubai-based techno-logistics transportation firm collected over $3.5 million in a recent funding round. The firm plans to scale up its services across the Gulf Cooperation Council (GCC), cites source. For the record, launched in 2017, Trukkin provides digital solutions to long-haul tru... Read More

Royal Dutch Shell’s India unit opens first lubricant lab in India

Published Date: 2019-05-22         Author: Pankaj Singh

Royal Dutch Shell’s India unit has recently announced that the company has opened its first lubricant laboratory in Bengaluru, its technological center. The company plans to expand its Research and Development (R&D) efforts for the country, as well as internationally, reports source. Sh... Read More

© 2019 Fractovia. All Rights Reserved